Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Duarte, California 91010


Purpose:

RATIONALE: Gathering information about cognitive function over time in postmenopausal women with breast cancer may help doctors learn about the long-term effects of aromatase inhibitor therapy and plan the best treatment. PURPOSE: This clinical trial is studying cognitive function in older postmenopausal women with stage I, stage II, or stage III breast cancer receiving hormone therapy and in healthy volunteers.


Study summary:

OBJECTIVES: - Explore the impact of treatment with an aromatase inhibitor on the cognitive function of postmenopausal women with stage I-III breast cancer vs in cancer-free, age-matched healthy volunteers. OUTLINE: Patients receive adjuvant anastrozole or letrozole in the absence of disease progression or unacceptable toxicity. Patients and healthy volunteers undergo cognitive function testing consisting of neuropsychological battery tests and complete self-reported questionnaires (e.g., Squire Memory Self-Rating Questionnaire, and FACT-B Quality of Life Measure) regarding cognitive ability, quality of life, fatigue, and psychosocial status. Patients and healthy volunteers also undergo geriatric assessment at baseline and after 6 months of initiation with aromatase inhibitor therapy.


Criteria:

DISEASE CHARACTERISTICS: - Meets 1 of the following criteria: - Patient diagnosed with breast cancer - Stage I-III disease - Estrogen receptor- and/or progesterone receptor-positive - Planning to start treatment with anastrozole or letrozole - Age-matched healthy volunteer (control) - No history of breast cancer - Not receiving adjuvant aromatase inhibitor therapy PATIENT CHARACTERISTICS: - Postmenopausal - Able to converse, write, and read English - No claustrophobia (patients participating in the PET scan correlative study) PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior hormonal therapy, including estrogen replacement therapy - No previous treatment with CNS radiation


NCT ID:

NCT00681928


Primary Contact:

Principal Investigator
Arti Hurria, MD
Beckman Research Institute


Backup Contact:

N/A


Location Contact:

Duarte, California 91010
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.